Compare ALEMBIC PHARMA with Lupin Ltd - Equitymaster

Helping You Build Wealth With Honest Research
Since 1996. Try Now

  • MyStocks

MEMBER'S LOGINX

     
Login Failure
   
     
   
     
 
 
 
(Please do not use this option on a public machine)
 
     
 
 
 
  Sign Up | Forgot Password?  

ALEMBIC PHARMA vs LUPIN - Comparison Results

LUPIN 
   Change

Lupin is a leading pharmaceutical company with a strong presence in anti-infective, cardiovascular and asthma. Apart from having a strong domestic presence, the company markets its products in the regulated markets of the US and Europe and semi-regul... More

DO YOU LIKE THESE REPORTS? TELL US!

Current Valuations

    ALEMBIC PHARMA LUPIN ALEMBIC PHARMA/
LUPIN
 
P/E (TTM) x 14.8 48.5 30.6% View Chart
P/BV x 3.4 2.5 137.3% View Chart
Dividend Yield % 1.1 0.0 -  

Financials

 ALEMBIC PHARMA   LUPIN
EQUITY SHARE DATA
    ALEMBIC PHARMA
Mar-19
LUPIN
Mar-19
ALEMBIC PHARMA/
LUPIN
5-Yr Chart
Click to enlarge
High Rs664986 67.3%   
Low Rs412720 57.2%   
Sales per share (Unadj.) Rs208.7369.5 56.5%  
Earnings per share (Unadj.) Rs31.013.4 231.2%  
Cash flow per share (Unadj.) Rs37.137.4 99.3%  
Dividends per share (Unadj.) Rs5.500-  
Dividend yield (eoy) %1.00-  
Book value per share (Unadj.) Rs144.2303.7 47.5%  
Shares outstanding (eoy) m188.52452.49 41.7%   
Bonus/Rights/Conversions -ESOP-  
Price / Sales ratio x2.62.3 111.7%   
Avg P/E ratio x17.463.6 27.3%  
P/CF ratio (eoy) x14.522.8 63.5%  
Price / Book Value ratio x3.72.8 132.8%  
Dividend payout %17.70-   
Avg Mkt Cap Rs m101,461386,064 26.3%   
No. of employees `000NA17.7 0.0%   
Total wages/salary Rs m7,46731,513 23.7%   
Avg. sales/employee Rs ThNM9,453.8-  
Avg. wages/employee Rs ThNM1,782.0-  
Avg. net profit/employee Rs ThNM343.0-  
INCOME DATA
Net Sales Rs m39,347167,182 23.5%  
Other income Rs m943,640 2.6%   
Total revenues Rs m39,441170,822 23.1%   
Gross profit Rs m8,73628,822 30.3%  
Depreciation Rs m1,15210,850 10.6%   
Interest Rs m1843,078 6.0%   
Profit before tax Rs m7,49318,534 40.4%   
Minority Interest Rs m11-89 -12.1%   
Prior Period Items Rs m-9338 -247.5%   
Extraordinary Inc (Exp) Rs m0-3,400 0.0%   
Tax Rs m1,5689,017 17.4%   
Profit after tax Rs m5,8446,066 96.3%  
Gross profit margin %22.217.2 128.8%  
Effective tax rate %20.948.7 43.0%   
Net profit margin %14.93.6 409.4%  
BALANCE SHEET DATA
Current assets Rs m19,577138,536 14.1%   
Current liabilities Rs m14,89661,299 24.3%   
Net working cap to sales %11.946.2 25.8%  
Current ratio x1.32.3 58.2%  
Inventory Days Days9084 107.1%  
Debtors Days Days45112 40.3%  
Net fixed assets Rs m27,097127,516 21.2%   
Share capital Rs m377905 41.7%   
"Free" reserves Rs m26,811136,517 19.6%   
Net worth Rs m27,188137,422 19.8%   
Long term debt Rs m4,99366,417 7.5%   
Total assets Rs m47,778279,494 17.1%  
Interest coverage x41.77.0 594.0%   
Debt to equity ratio x0.20.5 38.0%  
Sales to assets ratio x0.80.6 137.7%   
Return on assets %12.63.3 385.6%  
Return on equity %21.54.4 487.0%  
Return on capital %23.68.9 264.9%  
Exports to sales %00-   
Imports to sales %00-   
Exports (fob) Rs mNANA-   
Imports (cif) Rs mNANA-   
Fx inflow Rs m19,45359,414 32.7%   
Fx outflow Rs m6,06522,282 27.2%   
Net fx Rs m13,38837,132 36.1%   
CASH FLOW
From Operations Rs m8,12016,660 48.7%  
From Investments Rs m-7,556-32,825 23.0%  
From Financial Activity Rs m5907,441 7.9%  
Net Cashflow Rs m1,153-8,724 -13.2%  

Share Holding

Indian Promoters % 74.1 46.6 159.0%  
Foreign collaborators % 0.0 0.2 -  
Indian inst/Mut Fund % 2.9 11.3 25.7%  
FIIs % 9.1 31.9 28.5%  
ADR/GDR % 0.0 0.0 -  
Free float % 13.9 10.1 137.6%  
Shareholders   49,328 98,259 50.2%  
Pledged promoter(s) holding % 0.0 0.0 -  
NM: Not Meaningful
Source: Company Annual Reports, Regulatory Filings, Equitymaster

Compare ALEMBIC PHARMA With:   ABBOTT INDIA  NATCO PHARMA  AJANTA PHARMA  PFIZER  DR. DATSONS LABS  

Compare ALEMBIC PHARMA With:   MYLAN (US)  ACTAVIS (US)  ADCOCK INGRAM (S. Africa)  TEVA PHARMA (Israel)  



Today's Market

Sensex Slips Over 300 Points; Axis Bank & Tech Mahindra Top Losers(12:30 pm)

Share markets in India have extended early losses and are presently trading deep in the red. Barring consumer durables sector, all sectoral indices are trading in red with stocks in the telecom sector.

Related Views on News

ALEMBIC PHARMA Announces Quarterly Results (1QFY20); Net Profit Up 36.4% (Quarterly Result Update)

Aug 21, 2019 | Updated on Aug 21, 2019

For the quarter ended June 2019, ALEMBIC PHARMA has posted a net profit of Rs 1 bn (up 36.4% YoY). Sales on the other hand came in at Rs 9 bn (up 10.0% YoY). Read on for a complete analysis of ALEMBIC PHARMA's quarterly results.

LUPIN Announces Quarterly Results (1QFY20); Net Profit Up 49.3% (Quarterly Result Update)

Aug 8, 2019 | Updated on Aug 8, 2019

For the quarter ended June 2019, LUPIN has posted a net profit of Rs 3 bn (up 49.3% YoY). Sales on the other hand came in at Rs 44 bn (up 14.6% YoY). Read on for a complete analysis of LUPIN's quarterly results.

LUPIN 2018-19 Annual Report Analysis (Annual Result Update)

Jul 18, 2019 | Updated on Jul 18, 2019

Here's an analysis of the annual report of LUPIN for 2018-19. It includes a full income statement, balance sheet and cash flow analysis of LUPIN. Also includes updates on the valuation of LUPIN.

ALEMBIC PHARMA 2018-19 Annual Report Analysis (Annual Result Update)

Jun 13, 2019 | Updated on Jun 13, 2019

Here's an analysis of the annual report of ALEMBIC PHARMA for 2018-19. It includes a full income statement, balance sheet and cash flow analysis of ALEMBIC PHARMA. Also includes updates on the valuation of ALEMBIC PHARMA.

LUPIN Announces Quarterly Results (4QFY19); Net Profit Down 1.5% (Quarterly Result Update)

May 17, 2019 | Updated on May 17, 2019

For the quarter ended March 2019, LUPIN has posted a net profit of Rs 3 bn (down 1.5% YoY). Sales on the other hand came in at Rs 44 bn (up 77.8% YoY). Read on for a complete analysis of LUPIN's quarterly results.

More Views on News

Most Popular

Buying these Eight Stocks is Like Owning Your Own Business(Profit Hunter)

Sep 5, 2019

Everyone dreams of owning a business. Here is your chance.

7 Stocks to Buy in the Market Today(The 5 Minute Wrapup)

Sep 5, 2019

The stock market had a four-year bull run starting September 2013. Are we seeing a similar pattern now?

Don't Buy Lakshmi Vilas Bank...Buy this Private Sector Bank with 74% Upside(The 5 Minute Wrapup)

Sep 4, 2019

Lakshmi Vilas Bank is in a vicious cycle. The stock is already down 57% in 2019. Despite this, the retail investors increased their holding.

Buy these 7 Stocks if You Believe in India(The 5 Minute Wrapup)

Sep 12, 2019

News headlines predict gloom and doom for India these days. You should ignore them.

A Recession Proof Stock You Can Bet On(Profit Hunter)

Sep 10, 2019

Usually, the typical horizon period for my smallcap recommendations is 3 to 5 years. But if you ask me, this could be one business that you could own and pass on to future generations.

More

Get the Indian Stock Market's
Most Profitable Ideas

How To Beat Sensex Guide 2019
Get our special report, How to Beat Sensex Nearly 3X Now!
We will never sell or rent your email id.
Please read our Terms

ALEMBIC PHARMA SHARE PRICE


Sep 17, 2019 03:35 PM

TRACK ALEMBIC PHARMA

  • Track your investment in ALEMBIC PHARMA with Equitymaster's Portfolio Tracker. Set live price alerts, get research alerts and more. Get access now...
  • Add To MyStocks

MORE ON ALEMBIC PHARMA

ALEMBIC PHARMA 8-QTR ANALYSIS

COMPARE ALEMBIC PHARMA WITH

MARKET STATS